Clinical Trial Update: Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating escitalopram for anxiety in COPD exacerbations has been withdrawn. No results were reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Escitalopram (escitalopram)

Snippet

Sponsor: Hull University Teaching Hospitals NHS Trust | Conditions: Anxiety, COPD | Phase 3 | Status: WITHDRAWN